Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder characterized by chronic inflammation of the nerves and destruction of the protective myelin sheath, leading to progressive weakness and sensory dysfunction. Several pharmaceutical companies are involved in the development and manufacturing of treatments for CIDP.
Latest Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Updates:
Horizon Therapeutics plc: Received FDA approval for Tepezza (vilopamab) for the treatment of CIDP in April 2023, offering a new targeted therapy option for managing the condition.
Octapharma AG: Announced the expansion of its clinical trial program for Octopep™ (human anti-pentraxin antibody) for treating CIDP in November 2023, aiming to confirm its potential benefits.
Argenx SE: Partnered with a führender Forschungsverein to develop next-generation antibody-based therapies for CIDP and other autoimmune diseases in December 2023, focusing on innovative treatment mechanisms.
Regeneron Pharmaceuticals, Inc.: Published positive results from a Phase 2 clinical trial of their IL-6R inhibitor for treating CIDP in January 2024, suggesting potential for further development of this therapeutic approach.
Praxis Pharmaceuticals, Inc.: Received funding from a venture capital firm in February 2024 to advance the development of their novel oral medication for CIDP, targeting a previously unexplored pathway for treatment.
List of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key companies in the market:
Chronic Inflammatory Demyelinating Polyneuropathy Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)